Pharma BD Deal Intelligence

Taisho Pharmaceutical Co., Ltd. / Kaigene, Inc.

2026 · Licensing/Option · Complete

On 2026-07-30 Kaigene granted Taisho Pharmaceutical exclusive rights to develop and commercialise KG006, a next-generation human neonatal Fc receptor (hFcRn) inhibitor, in Japan. Kaigene receives a USD 5 million one-time upfront payment plus development, regulatory and cumulative net-sales milestones and tiered royalties. The agreement is intended to underpin a three-way multi-regional clinical trial collaboration among Kaigene, Taisho and Celltrion. Aggregate deal value not recorded - disclosed milestone figures span two currencies without a stated total.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Immunology deals